Вакцинопрофилактика ветряной оспы

15.12.2010

Литература

  1. Баранов А.А., Балашов Д.Н., Горелов А.В. и др. Предотвращение ветряной оспы средствами специфической профилактики в Беларуси, Казахстане, России и Украине (Заявление группы экспертов в области вакцинопро-филактики) // Педиатрическая фармакология. 2008. Т. 5. № 3. С. 6 - 14.
  2. Белозеров Е.С., Буланьков Ю.И. Болезни герпес-вирусной группы. -Элиста: АПП «Джангар», 2005. - 64 с.
  3. Иванова В.В. Инфекционные болезни у детей: Учебное пособие, -М.: Медицинское информационное агентство, 2002. - 928 с.
  4. Инфекционная заболеваемость в РФ в 2005 - 2006 гг. (Информационный сборник) / ФЦГиЭ МЗиСР РФ. - М., 2007. С. 5, 13, 20.
  5. Сорокина М.Н., Скрипченко Н.В. Вирусные энцефалиты и менингиты у детей. - М.: Медицина, 2004. - 416 с.
  6. Шаханина И.Л., Ясинский А.А. Концепция определения экономической эффективности вакцинопрофилактики // Эпидемиология и Вак-цинопрофилактика. 2010. № 4 (53). С. 74 - 80.
  7. Экономический ущерб от инфекционных болезней в Российской Федерации в 2005 и 2006 гг. в расчете на один средний случай и на все случаи за год. http://www.rospotrebnadzor.ru/docs/order.
  8. Asano Y., Nakayama H., Yazaki T. et al. Protection against varicella in household contacts by immediate inoculation with live varicella vaccine // Pediatrics. 1977. V. 59. P 3 - 7.
  9. Asano Y., Suga S., Yoshikawa T. et al. Experience and reason: twenty-year follow-up of potective immunity of the Oka strain live varicella vaccine // Pediatrics. 1994. V. 94. P. 524 - 526.
  10. CDC. Varicella-related deaths among adults - United States, 1997 // MMWR. 1997. V. 46 (11). P. 409 - 412.
  11. CDC. Varicella-related deaths among children - United States, 1997 // MMWR. 1998. V. 47 (12). P. 365 - 368.
  12. Centers for Disease Control and Prevention. Outbreak of varicella among vaccinated children - Michigan, 2003 // MMWR. 2004. V. 53. P. 389 - 392.
  13. Chaves S.S., Haber P., Walton K. et al. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995 - 2005 // J. Infect. Dis. 2008. V. 197 (Suppl. 2). P. 170 - 177.
  14. Choo PW., Donahue J.G., Manson J.E., Platt R. The epidemiology of varicella and its complications // J. Infect. Dis. 1995. V. 172. P. 706 - 712.
  15. Davis M.M., Patel M.S., Gebremariam A. Decline in varicella-related hos-pitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States // Pediatrics. 2004. V. 114. P. 786 - 792.
  16. Guris D., Jumaan A.O., Mascola L. et al. Changing varicella epidemiology in active surveillance sites - United States, 1995 - 2005 // J. Infect. Dis. 2008. V. 197 (Suppl. 2). P. 71 - 75.
  17. Ha K., Baba K., Ikeda T. et al. Application of a live varicella vaccine in children with acute leukemia or other malignancies without suspension of anticancer therapy // Pediatrics. 1980. V. 65. P. 346 - 350.
  18. Kuter B., Matthews H., Shinefield H. et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine // Pediatr. Infect. Dis. 2004. V. 23. P. 132 - 137.
  19. Lopez A.S., Guris D., Zimmerman L. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose? // Pediatrics. 2006. V. 117. P. 1070 - 1077.
  20. Ozaki T., Nishimura N., Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic // Vaccine. 2000. V. 18. P 2375 - 2380.
  21. Ozaki T., Nishimuraa N., Mutoa T. et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan // Vaccine. 2005. V. 23. P. 1205 - 1208.
  22. Parker A.A., Reynolds M.A., Leung J. et al. Challenges to implementing second-dose varicella vaccination during an outbreak in the absence of a routine 2-dose vaccination requirement - Maine, 2006 // J. Infect. Dis. 2008. V. 97 (Suppl. 2). P. 101 - 107.
  23. Prevention of varicella recommendations of the Advisory Committee on Immunization Practices (ACIP) // MMWR, 2007. V. 56. (RR-4).
  24. Recommended immunization schedules for persons aged 0 through 18 years - United States // MMWR. 2010. V. 58 (51, 52). P. 1 - 4.
  25. Recommended Adult Immunization Schedule - United States // MMWR. 2010. V. 59 (1). P. 1 - 4.
  26. Rue J.L., Lopez A., Ortega-Sanchez I. et al. Varicella outbreak reporting, response, management, and national surveillance // J. Infect. Dis. 2008. V. 197. P. 108 - 113.
  27. Sakaguchi M., Yamanaka T., Ikeda K. et al. IgE-immediate systemic reactions to gelatin included in the varicella vaccine // J. Allergy Clin. Immunol. 1997. V. 99. P. 263 - 264.
  28. Seward J.F., Marin M., Vazquez M. Varicella vaccine effectiveness in the US vaccination program: a review // J. Infect. Dis. 2008. V. 197 (Suppl. 2). P. 82 - 89.
  29. Steiner I., Kennedy P.G., Pachner A.R. The neurotropic herpes viruses: herpes simplex and Varicella zoster // Lancet Neurol. 2007. V. 6 (11). P. 1015 - 1028.
  30. Takahashi M. 25-years experience with the Biken Oka strain varicella vaccine // Paediatr. Drugs. 2001. V. 3 (4). P 285 - 292.
  31. Takahashi M., Asano Y., Kamiya H. et al. Development of varicella vaccine // J. Infect. Dis. 2008. V. 197 (Suppl. 2). P. 41 - 44.
  32. Varicella vaccines (WHO position paper) // Weekly Epid. Record. 1998. V. 73. № 32. P. 241 - 248.
  33. Vesikari T., Baer M., Willems P. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years // J. Pediatr. Infect. Dis. 2007. V. 26 (2). P. 153 - 158.
  34. Wise R.P, Salive M.E., Braun M.M. et al. Postlicensure safety surveillance for varicella vaccine // JAMA. 2000. V. 284. P. 271 - 279.